Trial Profile

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Gedatolisib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms VIKTORIA-2
Sponsors Celcuity

31 Mar 2025 According to a Celcuity media release, company is on track to enroll its first patient in Q2 2025
07 Jan 2025 Status changed from planning to not yet recruiting.
14 Nov 2024 According to a Celcuity media release, Site qualification activities to support activation of up to 200 sites across North America, Europe, Latin America, and Asia are on track.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com